Quipt Home Medical Corp

Quipt Home Medical Corp (QIPT) Stock Analysis

$3.650

0.000 (0.00%)At close

Loading chart…
High
3.650
Open
3.650
VWAP
3.65
Vol
1.36M
Mkt Cap
132.40M
Low
3.640
Amount
4.97M
EV/EBITDA, TTM
4.20

Quipt Home Medical Corp. provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. The Company's expertise spans across a full spectrum of respiratory care, providing an end-to-end solution for medical providers and patients. This includes technology enabled equipment offerings and specialized care for patients with cardio and pulmonary diseases, sleep disorders, mobility challenges, and other chronic disease management. The Company's healthcare products and services include sleep apnea and pap treatment, home medical equipment, home ventilation and custom mobility solutions. It has a 60% ownership interest in Hart Medical Equipment, which maintains strategic relationships with integrated health systems and freestanding community-based hospitals, embedding the business into the hospital discharge processes of more than 19 hospitals and affiliated care facilities across its network.

AI analysis of Quipt Home Medical Corp (QIPT)

hold

Quipt Home Medical Corp (QIPT) is not a good buy for a beginner, long-term investor at this time. The stock is undergoing an acquisition process that will result in delisting, reducing market transparency and liquidity. While the acquisition may enhance competitiveness, the lack of future trading opportunities and the current overbought technical indicators make it unsuitable for investment under the given scenario.

Valuation Metrics

The current forward P/E ratio for Quipt Home Medical Corp (QIPT) is -7.84, compared to its 5-year average forward P/E of -20.84.

Forward P/E

Fair
5Y Average P/E
-20.84
Current P/E
-7.84
Overvalued
79.51
Undervalued
-121.20

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
4.18
Current EV/EBITDA
4.20
Overvalued
5.21
Undervalued
3.16

Forward P/S

Fair
5Y Average P/S
0.73
Current P/S
0.51
Overvalued
1.03
Undervalued
0.43

Alphio AI Price Scenarios for QIPT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%QIPT

$1.66

Scenario price

B

Base

Base · 50%QIPT

$1.42

Scenario price

B

Bear

Bear · 25%QIPT

$1.29

Scenario price

Events Timeline

2026-03-16 (ET)

07:50:00

Quipt Home Medical Completes Share Acquisition Plan

2025-12-15 (ET)

16:21:00

Major Averages Decline as Markets Enter Final Week of 2025

12:00:00

Major Averages Lower as Investors Focus on Economic Indicators

11:20:00

Stifel Downgrades Quipt Home Medical to Sell with Price Target of C$5.10

07:40:00

Quipt Reports Q4 Revenue of $68.3M, Below Consensus

News

QIPT FAQ — answered by Alphio AI

Quipt Home Medical Corp. provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. The Company's expertise spans across a full spectrum of respiratory care, providing an end-to-end solution for medical providers and patients. This includes technology enabled equipment offerings and specialized care for patients with cardio and pulmonary diseases, sleep disorders, mobility challenges, and other chronic disease management. The Company's healthcare products and services include sleep apnea and pap treatment, home medical equipment, home ventilation and custom mobility solutions. It has a 60% ownership interest in Hart Medical Equipment, which maintains strategic relationships with integrated health systems and freestanding community-based hospitals, embedding the business into the hospital discharge processes of more than 19 hospitals and affiliated care facilities across its network. It operates in the Healthcare sector.

Quipt Home Medical Corp (QIPT) is not a good buy for a beginner, long-term investor at this time. The stock is undergoing an acquisition process that will result in delisting, reducing market transparency and liquidity. While the acquisition may enhance competitiveness, the lack of future trading opportunities and the current overbought technical indicators make it unsuitable for investment under the given scenario.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started